Amylyx Pharmaceuticals Inc. is a biotechnology company based in Cambridge, MA, focused on developing innovative therapies for neurodegenerative diseases. The company specializes in advancing treatments that target the underlying mechanisms of conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Through its proprietary platform, Amylyx aims to address significant unmet medical needs, leveraging scientific expertise to improve patient outcomes and enhance quality of life for those affected by these challenging disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

10 Patents

#231 in Cambridge, MA

#1,773 in Massachusetts

#29,866 in US

#56,047 in the World

Cambridge, MA, United States of America

Amylyx Pharmaceuticals Inc.

Forward Citations = 31

5 inventors:

Joshua Cohen (9 out of 9 patents)

Justin Klee (9 out of 9 patents)

David Wai Fung Ma (3 out of 3 patents)

4. Xiaofeng Xiong (1 out of 7 patents)

5. Debra Odink (1 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amylyx Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/amylyx-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]